Combination therapy for multiple sclerosis in children
https://doi.org/10.21508/1027-4065-2016-61-2-61-67
Abstract
The efficiency of combination therapy for multiple sclerosis was evaluated in 40 children aged 10 to 17 years. Two groups matched for major clinical and laboratory parameters were treated every 6 months during 3 years. Both groups received one cascade plasma filtration session using plasma Evaflux 2A (Japan) and then intravenous immunoglobulins G during 2 days. Unlike the comparison group (n=10), the study group (n=30) had additionally antiviral and immunomodulatory therapy; the volume and duration of which were determined by the presence or absence of Herpesviridae reactivation in cerebrospinal fluid (CSF) and/or blood. The performed therapy was established to have a positive effect in 90% of the patients in both groups, but the study group showed valid more significant results and achieved decreased reactivation of chronic herpesvirus infections (predominantly that with Epstein–Barr virus and herpesvirus 6) in CSF and blood and reductions in EDSS scores in 80% of cases, by an average of 61%, and in the annual rates of exacerbations by 46%.
About the Authors
N. V. Skripchenko
Research Institute of Children’s Infections, Federal Biomedical Agency;
Saint Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation
Russian Federation
Saint Petersburg
Russian Federation
Saint Petersburg
G. P. Ivanova
Saint Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation;
Academician I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Saint Petersburg
Russian Federation
Saint Petersburg
A. V. Surovtseva
Research Institute of Children’s Infections, Federal Biomedical Agency
Russian Federation
Saint Petersburg
Russian Federation
Saint Petersburg
E. Yu. Skripchenko
Saint Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation
Russian Federation
Saint Petersburg
Russian Federation
Saint Petersburg
K. V. Serednyakov
Research Institute of Children’s Infections, Federal Biomedical Agency;
Saint Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation
Russian Federation
Saint Petersburg
Russian Federation
Saint Petersburg
References
1. Гусев Е.И., Завалишин И.А., Бойко А.Н. Рассеянный склероз и другие демиелинизирующие заболевания. Москва, 2004; 540. (Gusev E.I., Zavalishin I.A., Bojko A.N. Multiple sclerosis and other demyelinating diseases. Moscow, 2004; 540.)
2. Скрипченко Н.В., Иванова Г.П., Железникова Г.Ф. Герпесвирусная инфекция у детей с рассеянным склерозом. Матер. V Юбилейного Балтийского конгресса Под. ред. В.В. Гузевой. СПб: Изд-во «Человек и его здоровье», 2015; 315–316. (Skripchenko N.V., Ivanova G.P., Zheleznikova G.F. Herpesvirus infections in children with MS. Mater. V Anniversary of the Baltic Congress. V.V. Guzeva (ed.). St. Petersburg: Publishing House of the « CHelovek i ego zdorov’e «, 2015; 315–316.)
3. Железникова Г.Ф., Иванова Г.П., Суровцева А.В. Иммунопатогенетические аспекты развития рассеянного склероза у детей. Матер. Третьего конгресса Евро-азиатского общества по инфекционным болезням. СПб, 2015; 17. (Zheleznikova G.F., Ivanova G.P., Surovtseva A.V. Immunopatogenetical aspects of multiple sclerosis in children. Mater. Third Congress of the Euro-Asian Society for Infectious Diseases. St. Petersburg, 2015; 17.)
4. Brissaud O., Palin K. Multiple sclerosis: pathogenesis and manifestations in children. Arch Pediatr 2010; 8: 9: 969–978.
5. Almohmeed Y.H., Avenell A. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and MS. PLoS ONE 2013; 8: 4: e61110.
6. Corrales I., Gimenez E. Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method. Clin Vaccine Immunol 2014; 21: 684–688.
7. Absoud M. Childhood CNS inflammatory demyelinating diseases. Pediatr Child Health 2010; 20: 9: 404–410.
8. Гузева В.И., Чухловина М.Л. Рассеянный склероз. Диагностика и лечение (возрастные аспекты). СПб: Фолиант, 2003; 174. (Guzeva V.I., Chukhlovina M.L. Multiple Sclerosis. Diagnosis and treatment (age sensitive). St. Petersburg: Folio, 2003; 174.)
9. Столяров И.Д., Петров А.М., Ивашкова Е.В. Современный взгляд на иммуномодуляцию при рассеянном склерозе. Патогенез 2010; 8: 1: 10–13. (Stolyarov I.D., Petrov A.M., Ivashkova E.V. The modern view of immunomodulation in multiple sclerosis. Patogenez 2010; 8: 1: 10–13.)
10. Yeh E.A., Waubant E., Krupp L.B. et al. Multiple Sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol 2010; 68: 437.
11. Kamate M., Chetal V., Tonape V. et al. Central nervous system inflammatory demyelinating disorders of childhood. Ann Indian Acad Neurol 2010; 13: 4: 289–292.
12. Скрипченко Н.В., Иванова Г.П., Суровцева А.В. и др. Демиелинизирующие заболевания нервной системы у детей (этиология, клиника, патогенез, диагностика, лечение). Научные труды: Современные подходы к диагностике, терапии и профилактике инфекционных заболеваний у детей. Под ред. Ю.В. Лобзина, Н.В. Скрипченко. Том 5. СПб, 2015; 103–197. (Skripchenko N.V., Ivanova G.P., Surovtseva A.V. et al. Demyelinating diseases of the nervous system in children (etiology, clinical, pathogenesis, diagnosis, treatment). Scientific Proceedings: Current approaches to diagnosis, therapy and prevention of infectious diseases in children. YU.V. Lobzin, N.V. Skripchenko (eds). Vol. 5. St. Petersburg, 2015; 103–197.)
13. Cкрипченко Н.В., Иванова Г.П., Железникова Г.Ф., Алексеева Л.А. Нейроиммунные, эндокринные и патобиохимические механизмы патогенеза лейкоэнцефалитов и рассеянного склероза Научные труды: Современные подходы к диагностике, терапии и профилактике инфекционных заболеваний у детей. Под ред. Ю.В. Лобзина, Н.В. Скрипченко. Том 4. СПб, 2014; 492–511. (Skripchenko N.V., Ivanov G.P., Zheleznikova G.F., Alekseeva L.A. Neuroimmune, endocrine and pathobiochemical leukoencephalitis mechanisms of pathogenesis, and multiple sclerosis. Scientific Proceedings: Current approaches to diagnosis, therapy and prevention of infectious diseases in children. Yu.V. Lobzin, N.V. Skripchenko (eds.). Vol. 4. St. Petersburg, 2014; 492–511.)
14. Иванова Г.П., Трофимова Т.Н., Команцев В.Н. Диссеминированный лейкоэнцефалит и рассеянный склероз: причинно-следственная взаимосвязь. Нейроинфекции у детей. Под ред. Н.В. Скрипченко. СПб.: «Тактик–Студио», 2015; 541–554. (Ivanova G.P., Trofimova T.N., Komantsev V.N. Disseminated leukoencephalitis and multiple sclerosis: a causal relationship. Neuroinfection in children. N.V. Skripchenko (ed.). St. Petersburg: “Taktik–Studio”, 2015; 541–554.)
15. Суровцева А.В. Совершенствование тактики ведения рассеянного склероза у детей. Автореф. дисс. … к.м.н.. СПб, 2015; 23. (Surovtseva A.V. Improved tactics of multiple sclerosis in children. Avtoref. diss. …k.m.n. St. Petersburg, 2015; 23.)
16. Murray P.R., Rosenthal S.M., Pfaller A. Viral Classification, Structure, and Replication. Med Microbiol 2013, 44: 393–409.
17. Кaynar L., Altuntas F. Therapeutic plasma exchange in patients with neurologic disease: retrospective multicenter study. Transfus Apher Sci 2008; 38: 2: 109–115.
18. Llufriu S., Castillo J., Blanco Y. et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 2009; 73: 12: 949–953.
19. Feasby T., Banwell B., Benstead T. et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007; 21: Suppl. 1: 57–107.
20. Stiehm E., Jordan S., Ballow М. еt al. Therapeutic use of immunoglobulins. Adv Pediatr 2010; 57: 185–218.
21. Малиновская В.В., Деленян Н.В., Ариненко Р.Ю. Виферон – комплексный противовирусный и иммуномодулирующий препарат для детей и взрослых. Руководство для врачей. М., 2006; 87. (Malinovskaya V.V., Delenyan N.V., Kharchenko R.Yu. Viferon – comprehensive antiviral and immunomodulatory drug for children and adults. Guidelines for doctors. M., 2006; 87.)
22. Hedegaard C., Krakauer M., Bendtzen K. et al. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 2008; 125: 2: 161–169.
23. Lan R.Y. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 2008; 31: 7–12.
24. Скрипченко Н.В., Иванова Г.П., Суровцева А.В. Опыт применения ронколейкина при энцефалитах у детей. Ж. неврологии и психиатрии им. С.С. Корсакова 2014; 5: 22–27. (Skripchenko N.V., Ivanova G.P., Surovtseva A.V. Experience with Roncoleukinum in children with encephalitis. Žurnal nevrologii i psihiatrii S. S. Korsakova 2014; 5: 22–27.)
Review
For citations:
Skripchenko N.V., Ivanova G.P., Surovtseva A.V., Skripchenko E.Yu., Serednyakov K.V. Combination therapy for multiple sclerosis in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2016;61(2):61-67. (In Russ.) https://doi.org/10.21508/1027-4065-2016-61-2-61-67
Views:
935
Email this article 